Potential Risks and Benefits of TRT
Testosterone replacement therapy (TRT) is a medical treatment designed to restore normal testosterone levels in men diagnosed with hypogonadism—a condition where the body does not produce adequate testosterone due to testicular or pituitary issues. While TRT can offer meaningful benefits for appropriately diagnosed patients, it also carries significant risks that require careful consideration and ongoing medical monitoring.
Understanding the distinction between treating genuine hypogonadism and using TRT for age-related testosterone decline is critical. The Endocrine Society emphasizes that terms like "age-related hypogonadism" blur the line between treatable disease and normal aging, and TRT is not recommended for otherwise healthy men seeking an anti-aging solution.
Who Is a Candidate for TRT?
A proper diagnosis of hypogonadism requires two key elements: symptoms consistent with low testosterone and consistently low blood testosterone levels confirmed through accurate laboratory testing. The Endocrine Society recommends at least two early-morning, fasting testosterone tests, with a common clinical threshold near 300 ng/dL.
Symptoms may include reduced sexual desire, fatigue, loss of muscle mass, increased body fat, and mood changes. However, these symptoms overlap with many other conditions—including sleep apnea, thyroid disorders, diabetes, and depression—so blood testing is essential for accurate diagnosis.
TRT is most clearly beneficial for men with hypogonadism caused by identifiable medical conditions affecting the testes, pituitary, or hypothalamus. For men who are overweight or obese without another identified cause, weight loss is typically the first-line treatment rather than TRT.
Potential Benefits of TRT
For men with appropriately diagnosed hypogonadism, TRT offers several well-documented benefits.
Sexual Function. Clinical trials have consistently shown that TRT improves sexual activity and sexual desire in men with low testosterone. A recent review of landmark trials found modest but clinically significant benefits on self-reported energy, mood, and sexual function.
Body Composition and Muscle. TRT increases lean body mass and muscle strength. An umbrella review of 121 randomized controlled trials involving over 20,000 men found that testosterone therapy improved lean muscle mass by 1.6 to 3.59 kg and improved leg press and leg extension strength. These effects on muscle mass and strength were observed without adverse effects on major cardiovascular events or all-cause mortality in the reviewed trials.
Bone Health. TRT increases bone mineral density in the spine and hip. However, the effects on fracture risk are more complicated, as discussed below.
Anemia Correction. TRT has been shown to correct anemia in men with hypogonadism.
Mood and Energy. Recent trials found improvements in depressive symptoms among men with mild to moderate symptoms, though TRT did not improve severe clinical depression.
Potential Risks of TRT
Despite its benefits, TRT carries several documented risks that require monitoring.
Cardiovascular Concerns. The TRAVERSE trial, involving more than 5,200 men, found no meaningful increase in heart attacks or strokes over a 1- to 4-year period. However, the same trial revealed approximately a 50% relative increase in pulmonary embolism (blood clots in the lungs) among testosterone-treated men. The Endocrine Society has called for further research to determine whether this risk is limited to men with underlying clotting disorders or applies more broadly.
Bone Fractures. Surprisingly, the TRAVERSE trial also found an increased incidence of bone fractures among testosterone-treated men, despite TRT's positive effects on bone density. This finding remains incompletely understood and is a high-priority area for further research .
Prostate Health. Long-term prostate cancer risk with TRT remains unestablished. The Endocrine Society notes that prostate cancer develops slowly, and existing trials may not have followed men long enough to detect increased risk. Screening and monitoring before and during treatment are essential.
Other Documented Risks. Mayo Clinic lists several additional risks associated with TRT:
Worsening of sleep apnea
Acne and skin reactions
Breast enlargement (gynecomastia)
Suppression of sperm production and testicular shrinkage
Excessive red blood cell production (polycythemia), which increases clot risk
Monitoring During Treatment
Once TRT is initiated, regular monitoring is essential. This typically includes:
Testosterone levels to ensure therapeutic range
Hematocrit to monitor for polycythemia
Prostate-specific antigen (PSA) for prostate health
Blood pressure and cardiovascular risk factors
The Endocrine Society emphasizes that risk assessment before starting treatment and careful monitoring during treatment remain essential, particularly given the unresolved questions about long-term safety.
Conclusion
TRT offers clear benefits for men with properly diagnosed hypogonadism, including improved sexual function, increased muscle mass and strength, and better bone density. However, it is not a benign treatment. Documented risks include increased pulmonary embolism, unexplained fracture risk, polycythemia, and unresolved questions about long-term prostate safety. TRT should not be used for normal age-related testosterone decline in otherwise healthy men. The decision to start TRT should be made in consultation with a healthcare provider, based on accurate diagnosis using standardized testing, and accompanied by ongoing monitoring throughout treatment.
If you think you might be a candidate for TRT, contact Total T Clinic today and get started with some bloodwork.